Zobrazeno 1 - 10
of 208
pro vyhledávání: ''
Autor:
Sushmita Pathy, Ajay Kumar Yadav, Mukesh Yadav, Lalit Kumar, Sreenivas Vishnubhatla, Deepali Jain, Sachin Khurana, Anant Mohan, Prabhat Singh Malik
Publikováno v:
Oncology. 99:389-396
Background: Before the approval of first-line immune checkpoint inhibitors, platinum doublets were the standard of care in patients with treatment-naïve advanced non-small cell lung cancer (NSCLC) without targetable driver mutations. Pemetrexed-plat
Autor:
Atsushi Naganuma, Tamon Nagashima, Satoru Kakizaki, Daichi Takizawa, Hirotaka Arai, Ken Shirabe, Takeshi Hatanaka, Toshio Uraoka, Norifumi Harimoto, Takashi Ueno, Hiroki Tojima, Masashi Namikawa
Publikováno v:
Oncology. 99:641-651
Aim: Atezolizumab plus bevacizumab (atezo + bev) shows a good overall survival (OS) in advanced hepatocellular carcinoma (HCC) patients. However, the OS of patients with nonviral infection is quite worse than that in those with viral infection. The p
Autor:
Kazuhiro Kitajima, Hirotoshi Ishigaki, Takashi Yokoi, Ryo Takahashi, Hiroshi Doi, Toshiyuki Minami, Akifumi Nakamura, Yasuhiro Nakajima, Takashi Kijima, Yuichi Koda, Kozo Kuribayashi
Publikováno v:
Oncology. 99:161-168
Background: Cisplatin-pemetrexed combination chemotherapy is the current standard primary treatment for malignant pleural mesothelioma (MPM). It was first approved for untreated and unresectable MPM in the 2003 National Comprehensive Cancer Network (
Autor:
Savtaj S. Brar, Carol Jane Swallow, Charles Henry Lim, Hao-Wen Sim, Jennifer J. Knox, Bryan A. Chan, Akina Natori, James Brierley, Osvaldo Espin-Garcia, Rebecca Wong, Jolie Ringash, Eric Chen, Elena Elimova, Sara Hafezi-Bakhtiari, John Kim, Raymond Woo-Jun Jang, Di Maria Jiang, Geoffrey Liu, Patrik Rogalla, Gail Darling, Stephanie Moignard
Publikováno v:
Oncology. 99:49-56
Background: Trimodality therapy (TMT) with neoadjuvant chemoradiotherapy (nCRT) using concurrent carboplatin plus paclitaxel (CP) followed by surgery is the standard of care for locoregional esophageal or gastroesophageal junction (GEJ) cancers. Alte
Autor:
Junya Kitadani, Toshiyasu Ojima, Keiji Hayata, Hiroki Yamaue, Masaki Nakamura, Masahiro Katsuda, Mikihito Nakamori
Publikováno v:
Oncology. 99:57-61
Objectives: A regimen of S-1 combined with oxaliplatin (SOX) has been widely used as the first-line regimen for advanced gastric cancer. To further improve the antitumor efficacy for gastric cancer patients with peritoneal metastasis, we added nab-pa
Autor:
Yosuke Suehiro, Hiroshi Aikata, Masataka Tsuge, Shinsuke Uchikawa, Yumi Kosaka, Akira Hiramatsu, Michio Imamura, Eisuke Murakami, Yuwa Ando, Kei Morio, Yasutoshi Fujii, Takashi Nakahara, K. Yamaoka, Kazuaki Chayama, Tomokazu Kawaoka, Shoichi Takahashi
Publikováno v:
Oncology. 98:727-733
Objective: Functional hepatic reserve is important when considering sequential tyrosine kinase inhibitor (TKI) therapy for patients with advanced hepatocellular carcinoma (HCC). We assessed albumin-bilirubin (ALBI) score and Child-Pugh class as indic
Autor:
Chia Che Wu, Meng Che Hsieh, Cheng-Hua Huang, Shih Yu Huang, Harvey Yu-Li Su, Po Hui Chiang, Chun-Chieh Huang, Kun Ming Rau, Jui Ming Liu, Hao Lun Luo, Ming Tse Sung
Publikováno v:
Oncology. 98:146-153
Objectives: Platinum-based chemotherapy is the standard treatment for metastatic urothelial carcinoma (mUC). However, considering elderly patients often experience comorbidities and frailty, the utility of cisplatin-based chemotherapy for elderly pat
Autor:
Francesca Platini, Alba Bianco, Carlo Resteghini, Donata Galbiati, Massimo Milione, Cristiana Bergamini, Paolo Bossi, Lisa Licitra, Salvatore Alfieri, Stefano Cavalieri, Federica Perrone, Laura D. Locati
Publikováno v:
Oncology. 97:112-118
Background: Recurrent or metastatic (R/M) skin squamous cell carcinoma (sSCC) not amenable of surgery or irradiation may benefit from systemic therapies. Epidermal growth factor receptor (EGFR) inhibitors and, more recently, immune checkpoint blocker
Autor:
Flora Cesario, Marco Merlano, Giorgio Borretta, Adele Latina, Nerina Denaro, Lauro Corrado, Fabio Bramardi
Publikováno v:
Oncology. 97:206-210
Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma in combination with everolimus. LEN-treate
Autor:
Kazuo Kobayashi, Takeshi Aoyama, Kensei Yamaguchi, Mitsukuni Suenaga, Takashi Yokokawa, Takeru Wakatsuki, Kenichi Suzuki, Toshihiro Hama, Kazuyoshi Kawakami, Erika Sugiyama, Hitoshi Sato
Publikováno v:
Oncology. 96:200-206
Purpose: Hand-foot skin reaction (HFSR) can deteriorate quality of life in patients receiving regorafenib. Cutaneous toxicity is a main adverse effect of multikinase inhibitors and has also been associated with clinical outcome. This study assessed t